Use of trimethoprim–sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study

Abstract

Aims

Data available on the fetal safety of trimethoprim–sulfamethoxazole exposure during pregnancy remains scarce and inconclusive. A previous study assessing the link between use TMP-SMX exposure during pregnancy and the risk of spontaneous abortion (SA) did not control for protopathic bias and indication bias.

Methods

We conducted a nested control study (n= 77 429 pregnancies including 7039 cases of SA and 70 390 controls) within the Quebec Pregnancy Cohort. For each case of SA, we selected 10 controls at the index date that were matched on gestational age and year of pregnancy. TMP-SMX exposure was defined as either having filled at least one prescription between the first day of gestation (1DG) and the index date, or as having filled a prescription before pregnancy but with a duration overlapping the 1DG (102 pregnancies exposed to TMP-SMX including 25 cases of SA and 77 controls).

Results

Adjusting for potential confounders, TMP-SMX exposure was associated with an increased risk of SA (AOR 2.94, 95% CI 1.89–4.57, 25 exposed cases). Similar results were found after controlling for indication bias and protopathic bias.

Conclusion

Given that this drug is widely use in HIV patients to prevent opportunistic infections and malaria, there is an urgent need to identify potential data sources in Africa for analysis of early pregnancy exposure to TMP-SMX

http://ift.tt/2EvZjuI